About Pelage Pharmaceuticals
Pelage Pharmaceuticals is a Healthcare company based in Los Angeles (United States) founded in 2018 by William Lowry, Heather Christofk, and Michael Jung. Pelage Pharmaceuticals has raised $150.8 million across 3 funding rounds from investors including Arch Venture Partners, Google Ventures and Main Street Advisors. Its chief executive, as recorded, is Daniel Gil. Its website pelagepharma.com draws about 57 thousand monthly visits. Pelage Pharmaceuticals offers products and services including PP405. Its focus areas include Life Sciences, Dermatology, Drugs and Stem Cell Therapy. Its legal entity is Pelage Pharmaceuticals, Inc. Its competitors include Stemson Therapeutics and dNovo; 2 of its 2 listed competitors have raised funding.
Company details
Developer of therapeutics for hair loss treatment in men and women. It provides a topical, non-invasive small molecule pharmacological platform that can be used to activate hair follicle stem cells and promote thick hair growth.
- Headquarters Los Angeles, United States
- Founders William Lowry, Heather Christofk, Michael Jung
- SectorsHealthcare
- Website pelagepharma.com
- Social LinkedIn
- Legal Name Pelage Pharmaceuticals, Inc.
- Total Equity Funding$150.8M (USD)
in 3 rounds
- Latest Funding Round$120M (USD), Series B
Oct 2025
- InvestorsArch Venture Partners
& 4 more
Products & Services of Pelage Pharmaceuticals
Pelage Pharmaceuticals offers a comprehensive portfolio of products and services, including PP405.
Topical treatment that activates dormant hair follicle stem cells for growth.
Funding Insights of Pelage Pharmaceuticals
Pelage Pharmaceuticals has successfully raised a total of $150.8M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $120 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $150.8M
- Total Rounds 3
- Last Round Series B — $120M
- First Round $16.8M
(Feb 2024)
- Investors Count 5
All 3 funding rounds of Pelage Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $120M | Series B | – | Arch Venture Partners, Google Ventures | |
| Aug 2024 | $14M | Series A | – | Google Ventures | |
| Feb 2024 | $16.8M | Series A | – | Google Ventures |
5 investors in total: 5 institutional.
Investors in Pelage Pharmaceuticals
Pelage Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Arch Venture Partners, Google Ventures and Main Street Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
A venture capital fund focused on life sciences investments. | 2019 | visionaryvc.com | Newport Beach, United States | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Trusted strategic advisor and investment partner in media and entertainment. | 1997 | mainstreetadvisors.com | ||
Investor details for Pelage Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pelage Pharmaceuticals
4 people are tracked at Pelage Pharmaceuticals (4 in leadership).
| Name | Role | Group |
|---|---|---|
William Lowry | Co-Founder & President | Leadership |
Heather Christofk | Co-Founder | Leadership |
Michael Jung | Co-Founder | Leadership |
Daniel Gil | CEO | Leadership |
Complete people profiles for Pelage Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pelage Pharmaceuticals
3 dated milestones of Pelage Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Pelage Pharmaceuticals is founded.
- Funding First funding round of $16.8M.
- Funding Latest funding round, Series B, of $120.0M.
Competitors of Pelage Pharmaceuticals
Pelage Pharmaceuticals has 2 listed competitors in our database, 2 of them funded. They include Stemson Therapeutics and dNovo.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| stemsontx.com | 2019 | San Diego, United States | $22.5M | Stem cell-based therapy for hair growth is developed using iPSCs. | ||
| dnovobio.com | 2018 | San Francisco, United States | $2.7M | Developer of a hair loss treatment using reprogrammed stem cells |
Detailed competitors of Pelage Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pelage Pharmaceuticals
The website of Pelage Pharmaceuticals (pelagepharma.com) receives about 56.9K visits a month.
- Monthly visits56.9K
▲ 20.7% vs previous month
Websites whose visitors overlap most with Pelage Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
dermatologytimes.com | dermatologytimes.com | 100% | #199,743 | – | |
thedermdigest.com | thedermdigest.com | 94% | #768,419 | – | |
baumanmedical.com | baumanmedical.com | 86% | #763,542 | – | |
| bosley.com | 74% | 296.8K | #204,627 | View details | |
| clinicalleader.com | 63% | 680.7K | #948,222 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Pelage Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Pelage Pharmaceuticals (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pelage Pharmaceuticals
Complete news archive for Pelage Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pelage Pharmaceuticals
Pelage Pharmaceuticals was founded in 2018 and raised its 1st funding round 6 years after it was founded.
Pelage Pharmaceuticals is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Daniel Gil is the CEO of Pelage Pharmaceuticals, as recorded in our data.
Pelage Pharmaceuticals is a funded company, having raised a total of $150.8M across 3 funding rounds to date. The company's 1st funding round was a Series A of $16.8M, raised on Feb 2024.
Developer of therapeutics for hair loss treatment in men and women. It provides a topical, non-invasive small molecule pharmacological platform that can be used to activate hair follicle stem cells and promote thick hair growth.
Pelage Pharmaceuticals's top competitors include Stemson Therapeutics and dNovo.
Pelage Pharmaceuticals offers PP405.
Pelage Pharmaceuticals has 5 investors. Key investors include Arch Venture Partners, Google Ventures, Main Street Advisors, Visionary Ventures, and YK Bioventures.
Pelage Pharmaceuticals operates through Pelage Pharmaceuticals, Inc..